Procizumab is under clinical development by 4TEEN4 Pharmaceuticals and currently in Phase I for Cardiogenic Shock. According to GlobalData, Phase I drugs for Cardiogenic Shock does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Procizumab LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Procizumab overview
Procizumab is under development for the treatment of patients with acute myocardial depression including acute heart failure and cardiogenic shock. The drug candidate is a humanized monoclonal antibody that targets dipeptidyl peptidase 3 (DPP3) and is administered by intravenous route.
4TEEN4 Pharmaceuticals overview
4TEEN4 Pharmaceuticals (formerly Sphingotec Therapeutics GmbH), is a biopharmaceutical company developing Procizumab, a novel therapeutic anti-DPP3 antibody for treatment of acute myocardial depression. The company is headquartered in Germany.
For a complete picture of Procizumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
